Skip to content

A study to compare efficacy of Dashmulyadi Kwatha and Shringyadi churna in the management of Tamaka Shwasa with special reference to Bronchial Asthma

A comparative study to evaluate the efficacy of Dashmulyadi Kwatha and Shringyadi Churna in the management of Tamaka Shwasa with special reference to Bronchial Asthma - nil

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2025/03/083297
Enrollment
120
Registered
2025-03-25
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: J454- Moderate persistent asthma

Interventions

None listed

Sponsors

Dr.Kimmi Seth
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patient having classical features of Tamaka Shwasa. Presence of symptoms of airflow obstruction 2 or more of cough, wheezing, dyspnoea. Airflow obstruction is atleast partially reversible. Oxygen saturation greater than 90 percent Cases included from intermittent mildly persistent to moderate persistent asthma. PEFR more than 60 percent of the predicted value.

Exclusion criteria

Exclusion criteria: PEFR less than equals to 60 percent of the predicted value orless than 100 litre per min equals to Severe Exacerbation(Status Asthmaticus). Blood Oxygen saturation less than 90 percent Asadhya Lakshanas of Tamaka Shwasa. The patient with history of Tuberculosis, COPD, Emphysema, Chronic airway obstruction, Status Asthmaticus, Cardiac asthma, CAD. History of Endocrine disorders like diabetes mellitus, thyroidism. known case of Hypertension Other complicated respiratory diseases having any organic lesion such as tumor or any anatomical defect in airway. If the patient exhibits short seasonal changes of less than 4 weeks duration. Any other physical and surgically ill patient will be excluded. Severe exacerbation inspite of medication.

Design outcomes

Primary

MeasureTime frame
Complete Remission Markedly Improved Moderately Improved Mildly Improved UnchangedTimepoint: 15th day, 30th day, 45th day, 60th day

Secondary

MeasureTime frame
Exacerbations in signs and symptomsTimepoint: 30th day, 60 th day after the completion of trial.

Countries

India

Contacts

Public ContactProf Amitabh Singh

Desh Bhagat University

asinghay@gmail.com9815526868

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026